Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.

British journal of haematology - 1 Nov 2008

Vasavda Nisha, Badiger Sheela, Rees David, Height Sue, Howard Jo, Thein Swee Lay

Abstract excerpt

Hydroxycarbamide (HC), although a key drug therapy in sickle cell disease (SCD), does not result in a clinical response in all patients. Increases in fetal haemoglobin (HbF) and mean corpuscular volume of erythrocytes are standard clinical measures of HC efficacy in SCD. Genetic studies have determined that the majority of HbF regulation occurs outside the beta-globin locus. Approximately 30% of SCD patients have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Globins
Share to Anemia, Sickle Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Erythrocyte Count

Share to Erythrocyte Indices

Share to Fetal Hemoglobin

Share to Hydroxyurea

Share to Thalassemia

Source

Identifiers

PMID: 18764867
DOI: 10.1111/j.1365-2141.2008.07375.x

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.PMID 18764867Read ↗

Hydroxyurea (hydroxycarbamide) for sickle cell disease.Semantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseSemantic proximity Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.Semantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Fixed Low-Dose Hydroxyurea Therapy: A Strategy for Reducing Emergency Room Visits and Improving Treatment Adherence in Paediatric Sickle Cell Anaemia in Resource-Limited SettingsSemantic proximity Read ↗

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.Semantic proximity Read ↗

Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.Semantic proximity Read ↗

Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.Semantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Semantic proximity Read ↗

Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.